2024
Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer
Cecchini M, Salem R, Robert M, Czerniak S, Blaha O, Zelterman D, Rajaei M, Townsend J, Cai G, Chowdhury S, Yugawa D, Tseng R, Arbelaez C, Jiao J, Shroyer K, Thumar J, Kortmansky J, Zaheer W, Fischbach N, Persico J, Stein S, Khan S, Cha C, Billingsley K, Kunstman J, Johung K, Wiess C, Muzumdar M, Spickard E, Aushev V, Laliotis G, Jurdi A, Liu M, Escobar-Hoyos L, Lacy J. Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer. JAMA Oncology 2024, 10: 1027-1035. PMID: 38900452, PMCID: PMC11190830, DOI: 10.1001/jamaoncol.2024.1575.Peer-Reviewed Original ResearchProgression-free survivalPancreatic ductal adenocarcinomaOverall survivalCtDNA levelsPhase 2 nonrandomized controlled trialAnalysis of circulating tumor DNAMedian progression-free survivalResectable pancreatic ductal adenocarcinomaControlled trialsAssess surgical candidacyBaseline ctDNA levelModified 5-fluorouracilResectable pancreatic cancerPancreatic protocol computed tomographyAssociated with recurrenceTumor molecular featuresAggressive malignant tumorKaplan-Meier estimatesRandomized clinical trialsStandard of careCtDNA-positivePreoperative cyclesNonrandomized controlled trialsUnresectable diseaseModified FOLFIRINOX
2021
Somatic Mutations in Circulating Cell-Free DNA and Risk for Hepatocellular Carcinoma in Hispanics
Jiao J, Sanchez J, Thompson E, Mao X, McCormick J, Fisher-Hoch S, Futreal P, Zhang J, Beretta L. Somatic Mutations in Circulating Cell-Free DNA and Risk for Hepatocellular Carcinoma in Hispanics. International Journal Of Molecular Sciences 2021, 22: 7411. PMID: 34299031, PMCID: PMC8304329, DOI: 10.3390/ijms22147411.Peer-Reviewed Original ResearchConceptsAdvanced liver fibrosisCell-free DNAHigher cfDNA concentrationsHepatocellular carcinomaLiver fibrosisCfDNA concentrationHCC patientsOverall survivalAdvanced fibrosisHCC risk predictionShorter overall survivalMajor risk factorNon-invasive markerPlasma cell-free DNADetectable mutationsSomatic mutationsCirculating Cell-Free DNARisk factorsHCC developmentCancer-associated genesDeath outcomesFibrosisPatientsNonsynonymous mutationsRisk prediction
2017
Prevalence of Aflatoxin-associated TP53R249S mutation in Hepatocellular Carcinoma in Hispanics in South Texas
Jiao J, Niu W, Wang Y, Baggerly K, Ye Y, Wu X, Davenport D, Almeda J, Betancourt-Garcia M, Forse R, Stevenson H, Watt G, McCormick J, Fisher-Hoch S, Beretta L. Prevalence of Aflatoxin-associated TP53R249S mutation in Hepatocellular Carcinoma in Hispanics in South Texas. Cancer Prevention Research 2017, 11: 103-112. PMID: 29089331, PMCID: PMC5811406, DOI: 10.1158/1940-6207.capr-17-0235.Peer-Reviewed Original ResearchConceptsAdvanced fibrosisHepatocellular carcinomaCell-free DNAHCC patientsHispanic subjectsShorter overall survivalPlasma cell-free DNAAsian HCC patientsOverall survivalWorse prognosisAflatoxin exposureHigh incidenceCirrhosisHCC tumorsPromising biomarkerDietary exposureFibrosisYounger agePatientsDroplet digital PCRHispanicsSomatic mutationsFamily membersUpstream regulatorSubjects